3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Hepatocellular
15
Small Cell Lung Carcinoma
11
Triple Negative Breast Neoplasms
9
Neoplasms
8
Colorectal Neoplasms
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Lung Neoplasms
5
Carcinoma, Renal Cell
5
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Venous Thrombosis
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Prostatic Neoplasms, Castration-Resistant
1
Peritoneal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non-Small-Cell Lung
1
Interventions
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Muscle-invasive Bladder Cancer
×
atezolizumab
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA